Government policies that stimulate biosimilars that drive demand

DublinAnd the 5 July 2022 /PRNewswire/ – “The Biosimilars Market in EuropeAdded: Industry Trends, Share, Size, Growth, Opportunities and Forecast 2022-2027″ report added to ResearchAndMarkets.com Show.

biosimilars market in Europe reached the value 6,735 million USD In 2021. Looking to the future, the publisher expects to reach the market 25,446 million US dollars By 2027, show a compound annual growth rate 22.8% during 2022-2027.

drivers

Biosimilars are less expensive than their branded counterparts as they do not require extensive research and testing which saves money and time; Thus reducing costs. Moreover, they also have short marketing times because the launch of the biosimilar does not require extensive marketing as the safety and efficacy profile for their brand counterparts has already been established.

Many popular biopharmaceuticals are expected to lose patent protection over the next five to ten years. The expiration of patents and other intellectual property rights is expected to create huge opportunities for biosimilar manufacturers

Europe’s population is aging with around a fifth of the total EU population over the age of 65. This has resulted in a significant increase in the burden of lifestyle diseases in the region. The prevalence of diseases such as diabetes, autoimmune diseases, tumors, etc. is increasing rapidly in Europe. This is also expected to drive market growth over the next few years

As a result of rising healthcare costs, governments in a number of European countries have formulated policies that incentivize physicians, pharmacists, and patients in favor of biosimilars over branded biologics.

Main market segmentation:

Breakdown by country:

• Italia

• Germany

• United kingdom

• France

• Spain

• rest of Europe

molecule dissociation:

• infliximab

• Insulin glargine

• alpha of epoet

• etanercept

• filgrastim

• somatropin

• rituximab

• follitropin alpha

• adalimumab

Signal break up:

• autoimmune diseases

• blood disorder

• diabetic

• Oncology

• lack of growth

• female infertility

The story continues

Breakdown by type of manufacture:

• In-house manufacturing

• manufacturing contract

Some of the leading companies operating in the European biosimilars market include:

• Novartis

• Pfizer

• teva

• Sell ​​Tryon

• Samsung Bioepis

• Amgen

• botox

• Ratipharm

• Milan

• Merck Sharp and Dom

• Eli Lilly

• Accord Healthcare Limited

• Boehringer Ingelheim

• Hexal Ag

• Stada Medical Products Ag

This report provides an in-depth look at the European Biosimilars Market covering all its essential aspects. This ranges from a comprehensive market overview to the minute details of industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must read for entrepreneurs, investors, researchers, consultants, business strategists and all those who have any type of equity or are planning to penetrate the European biosimilars market in any way.

Main topics covered:

1 Introduction

2 Scope and methodology

3 Executive Summary

4 Europe Biosimilars Market – Introduction

5 Biosimilars market in Europe
5.1 Market Overview
5.2 Historical and current market trends
5.3 Impact of COVID-19
5.4 Market segmentation by country
5.5 Market Breakdown by Molecule
5.6 Market Breakdown by Index
5.7 Market Segmentation by Manufacturing Type
5.8 patent scene
5.9 Market Outlook

6 Market segmentation by country

7 Market disintegration by molecule

8 Market Breakdown by Manufacturing Type

9 Breakdown of the market with the index

10 European Biosimilars Market: SWOT Analysis

11 European Biosimilars Market: Value Chain Analysis
11.1 Characterization of the current innovative drug
11.2 Research and development
11.2.1 Characterization of biosimilars
11.2.2 Develop a unique cell line
11.3 Product Development
11.3.1 Pre-test
11.3.2 Intermediate Clinical Tests (PK/PD)
11.3.3 Clinical confirmatory phase III
11.4 Formulation of the final product
11.5 Marketing and Distribution

12 Porter’s Five Forces Analysis

13 Price Analysis
13.1 Key Price Indicators
13.2 Price trends

14 Requirements for establishing a generic drug manufacturing plant
14.1 Manufacturing Process
14.2 Raw Material Requirements
14.3 Raw Material Pictures
14.4 Land and Building Requirements
14.5 Machinery and Infrastructure Requirements
14.6 Machine Pictures
14.7 Plant layout
14.8 Packaging requirements
14.9 Facilities Requirements
14.10 Manpower Requirements

For more information on this report, visit https://www.researchandmarkets.com/r/f1fvjd

Media contact:

Research and Markets
Laura Wooddirector, mentor
press@researchandmarkets.com

For EST office hours, call +1-917-300-0470
For US/Canada, call toll free +1-800-526-8630
For GMT office hours, call +353-1-416-8900

US Fax: 607-646-1904
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/european-biosimilar-market-report-2022-2027-government-policies-incentivising-biosimilars-driving-demand-301580668.html

SOURCE Research & Markets